IN8bio Earnings Call Transcripts
Fiscal Year 2026
-
Gamma delta T cell therapies showed promising clinical results in glioblastoma and leukemia, with no major toxicities and statistically significant survival benefits. The proprietary T-cell engager platform targets autoimmune diseases with reduced toxicity, and key clinical and preclinical milestones are expected later this year.
-
Gamma delta T cell therapies show long-term remissions in AML and glioblastoma, with repeat dosing linked to improved survival. A new T cell engager platform demonstrates potent B cell depletion and reduced cytokine release, with key animal data and regulatory milestones expected later this year.
-
The company presented strong clinical data for its gamma-delta T cell therapies, showing significant survival benefits in glioblastoma and progress in leukemia and T cell engager programs. Recent financing secures operations through 2027, with key data and regulatory milestones expected this year.
Fiscal Year 2025
-
New data unveiled for a gamma-delta T cell engager platform targeting both cancer and autoimmune diseases, with clinical trials showing durable remissions and reduced toxicities. The approach offers potent B cell depletion without lymphodepletion, aiming for safer, more accessible therapies.
-
Gamma delta T-cell therapies show promising long-term remissions in AML and glioblastoma, with no relapses in AML patients and survival rates surpassing benchmarks. New data on T-cell engagers and solid tumor programs are expected later this year.
-
A phase I trial of allogeneic gamma-delta T cells (INB-100) in high-risk AML patients post-transplant showed no relapses and 100% survival at one year, with a strong safety profile and significant improvement over historical controls. Expansion to more patients and centers is ongoing.
-
Gamma delta T cell therapies show strong safety and efficacy, with durable remissions in leukemia and promising results in glioblastoma. Multiple clinical and preclinical data updates are expected this year, supported by a robust team and sufficient funding.
Fiscal Year 2024
-
A strategic shift prioritizes INB-100 for leukemia, with early data showing durable remissions and strong safety. INB-200 and other assets are paused or seeking partnerships amid a tough funding climate, and workforce reductions aim to extend cash runway.
-
Multiple clinical programs are advancing, with INB-200 and INB-100 showing durable remissions in GBM and leukemia, respectively. Gamma delta T cell therapies demonstrate unique persistence and safety, with upcoming data and trial updates expected later this year.